(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer...
Stats | |
---|---|
今日成交量 | 45 339.00 |
平均成交量 | 225 248 |
市值 | 87.78M |
EPS | $0 ( 2024-05-03 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.17 |
ATR14 | $0.0290 (1.27%) |
BeyondSpring Inc 相关性 - 货币/商品
BeyondSpring Inc 财务报表
Annual | 2023 |
营收: | $1.75M |
毛利润: | $1.75M (100.00 %) |
EPS: | $-0.540 |
FY | 2023 |
营收: | $1.75M |
毛利润: | $1.75M (100.00 %) |
EPS: | $-0.540 |
FY | 2022 |
营收: | $1.35M |
毛利润: | $1.35M (100.00 %) |
EPS: | $-0.930 |
FY | 2021 |
营收: | $1.35M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.14 |
Financial Reports:
No articles found.
BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。